Apolipoprotein M can discriminate HNF1A-MODY from Type 1 diabetes

Diabetic Medicine

Volumn 30, Issue 2, 2013, Pages 246-250

  Mughal, S A ^a,b   Park, R ^c   Nowak, N ^d   Gloyn, A L ^a,b   Karpe, F ^a,b   Matile, H ^e   Malecki, M T ^d   Mccarthy, M I ^b,f   Stoffel, M ^c   Owen, K R ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c Institute of Molecular Systems Biology   (Switzerland)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN M; C PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL;

EID: 84872698621     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12066     Document Type: Article

References (18)

1. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). Br Med J 2011; 343: d6044.
2. Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset Type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206-1212.
3. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 2010; 53: 2504-2508.
4. Owen KR, Skupien J, Malecki MT. The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes. Diabetes Res Clin Pract 2009; 86: S15-21.
5. Xu N, Dahlback B. A novel human apolipoprotein (apoM). J Biol Chem 1999; 274: 31286-31290.
6. Richter S, Shih DQ, Pearson ER, Wolfrum C, Fajans SS, Hattersley AT et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1alpha: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003; 52: 2989-2995.
7. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, Wanic K et al. Evaluation of apolipoprotein M serum concentration as a biomarker of HNF-1α MODY. Rev Diabet Stud 2007; 4: 231-235.
8. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T et al. An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010; 267: 316-321.
9. Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011; 219: 855-863.
10. Axler O, Ahnstrom J, Dahlback B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res 2007; 48: 1772-1780.
11. McDonald TJ, McEneny J, Pearson ER, Thanabalasingham G, Szopa M, Shields BM et al. Lipoprotein composition in HNF1A-MODY: differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta 2012; 413: 927-932.
12. Owen KR, Thanabalasingham G, James TJ, Karpe F, Farmer AJ, McCarthy MI et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010; 33: 1919-1924.
13. Thanabalasingham G, Shah N, Vaxillaire M, Hansen T, Tuomi T, Gasperikova D et al. A large multi-centre European study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 2011; 54: 2801-2810.
14. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes. Diabet Med 2011; 28: 1028-1033.
15. Plomgaard P, Dullaart RPF, de Vries R, Groen AK, Dahlback B, Nielsen LB. Apolipoprotein M predicts pre-β-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 2009; 266: 258-267.
16. Mosialou I, Krasagakis K, Kardassis D. Opposite regulation of the human apolipoprotein M gene by hepatocyte nuclear factor 1 and Jun transcription factors. J Biol Chem 2011; 286: 17259-17269.
17. Wolfrum C, Howell JJ, Ndungo E, Stoffel M. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem 2008; 283: 16940-16949.
18. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011; 108: 9613-9618.